PSORIASIS VULGARIS
Clinical trials for PSORIASIS VULGARIS explained in plain language.
Never miss a new study
Get alerted when new PSORIASIS VULGARIS trials appear
Sign up with your email to follow new studies for PSORIASIS VULGARIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Natural cream tested for stubborn skin condition
Disease control CompletedThis study tested whether a cream made from plant compounds called coumarins could help control plaque psoriasis. 88 adults with mild to moderate psoriasis applied either the cream or a placebo for 8 weeks. Researchers measured changes in skin redness, thickness, scaling, and how…
Matched conditions: PSORIASIS VULGARIS
Phase: PHASE2 • Sponsor: Psoriasis Research Institute of Guangzhou • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Higher dose tested for psoriasis patients who weigh more
Disease control CompletedThis study tested if a higher, adjustable dose of the psoriasis medication brodalumab works better for people who weigh over 120 kg. It compared this adjusted dose to the standard dose over 52 weeks. The goal was to see if the higher dose could improve skin clearance and quality …
Matched conditions: PSORIASIS VULGARIS
Phase: PHASE4 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Can psoriasis patients safely cut their medication dose in half?
Disease control CompletedThis study tested whether carefully reducing the dose of newer psoriasis medications (IL17 or IL23 inhibitors) works as well as continuing the standard dose. It involved 244 patients whose psoriasis was already well-controlled. The goal was to see if lower doses could maintain co…
Matched conditions: PSORIASIS VULGARIS
Phase: PHASE4 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Light-Activated gel shows promise for psoriasis skin relief
Disease control CompletedThis study tested a new topical ointment called SGX302, which is activated by visible light, to see if it could improve skin lesions in people with mild-to-moderate plaque psoriasis. Fifteen participants applied the treatment to their skin for an 18-week course. The main goal was…
Matched conditions: PSORIASIS VULGARIS
Phase: PHASE2 • Sponsor: Soligenix • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC